Pharmafile Logo
Pharmafocus logo
Advanced Search

Novo Nordisk

Showing 15 posts of 188 posts found.

hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

August 22, 2025
Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …

News

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation

August 19, 2025
Mergers and Acquisitions, Research and Development BioMed X, Novo Nordisk, Pharmacy, drug development, therapeutic peptides

BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of therapeutic peptides – a major …

News
obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

July 8, 2025
Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …

News
weight-2036971_960_720

Novo Nordisk’s therapy delivers significant weight loss in trial

June 25, 2025
Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions

Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …

News
blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025
Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …

News
researchers_credit_neusentis_pfizer

Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025

May 12, 2025
Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide

Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …

News

Novo Nordisk Foundation expands ambitious Challenge Programme internationally 

April 30, 2025
Research and Development Challenge Programme, Denmark, Novo Nordisk, Pharmacy, international

The Novo Nordisk Foundation Challenge Programme, a leading open competition grant programme, invites researchers outside of Denmark to participate and …

News

Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial

April 1, 2025
Research and Development Cardiology, Novo Nordisk, cardiometabolic diseases, research and development

Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse …

News

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

March 22, 2024
Medical Communications CHMP, Diabetes, Novo Nordisk, diabetes

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended …

News

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

February 23, 2024
Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …

News

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

January 10, 2024
Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …

News
glsun-mall-9xmv81sz5fw-unsplash

Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

November 10, 2023
Manufacturing and Production Chronic Diseases, Denmark, Novo Nordisk, investment, manufacturing

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …

News

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023
Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …

News

Novo Nordisk launches Wegovy in the UK

September 4, 2023
Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …

News

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

August 31, 2023
Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026